Hepatitis C and interferon: fewer cases of liver cancer


Prescrire International 22(140): 191

2013


ISSN/ISBN: 1167-7422
PMID: 23951600
Document Number: 668579
Data on the risk of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C participating in placebo-controlled trials of interferon have been published after 3 to 9 years of follow-up. Among patients with chronic hepatitis C and either fibrosis or cirrhosis, interferon greatly reduced the risk of hepatocellular carcinoma after 8 years or more, especially when viral load was below the limit of detection.

Document emailed within 1 workday
Secure & encrypted payments